Page last updated: 2024-09-04

atrasentan and Ovarian Neoplasms

atrasentan has been researched along with Ovarian Neoplasms in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (83.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO	1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Padley, RJ; Rosanò, L; Salani, D; Spinella, F; Venuti, A	1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Salani, D; Spinella, F; Venuti, A	1
Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F	1
Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F	1
Lalich, M; Liu, G; McNeel, DG; Wilding, G	1

Reviews

1 review(s) available for atrasentan and Ovarian Neoplasms

Article	Year
Endothelin receptor antagonists in cancer therapy. Cancer investigation, 2007, Volume: 25, Issue:8 Topics: Atrasentan; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Signal Transduction; Sulfonamides	2007

Trials

1 trial(s) available for atrasentan and Ovarian Neoplasms

Article	Year
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting	2010

Article

Year

Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.

Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting

2010

Other Studies

4 other study(ies) available for atrasentan and Ovarian Neoplasms

Article	Year
ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clinical science (London, England : 1979), 2002, Volume: 103 Suppl 48 Topics: Atrasentan; Binding, Competitive; Cell Division; Endothelin Receptor Antagonists; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ovarian Neoplasms; Pyrrolidines; Receptor, Endothelin A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2002
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer research, 2003, May-15, Volume: 63, Issue:10 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Division; Drug Synergism; Endothelial Growth Factors; Endothelin Receptor Antagonists; Female; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays	2003
Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14 Topics: Animals; Atrasentan; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indomethacin; Isoenzymes; Luciferases; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Nude; Nitrobenzenes; Ovarian Neoplasms; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyrrolidines; Receptor, Endothelin A; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays	2004
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan. Journal of cardiovascular pharmacology, 2004, Volume: 44 Suppl 1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays	2004